Flavoxate, a Potent Phosphodiesterase Inhibitor

Overview

Journal Arch Int Pharmacodyn Ther

Specialty Pharmacology

Date 1975 Feb 1

PMID 167667

Citations 4

Authors

M Conti

I Setnikar

Affiliations

Soon will be listed here.

Abstract

The c-AMP phosphodiesterase inhibiting properties of flavoxate and of its main metabolite i.e. 3-methylflavone-8-carboxylic acid (MFCA), were assayed in vitro and compared to those of theophylline. Flavoxate and MFCA are competitive phosphodiesterase inhibitors, and are 21 and respectively 5 times more potent than theophylline. The smooth muscle relaxing activity of flavoxate possibly relies on this enzymatic mechanism.

Citing Articles

Flavoxate in urogynecology: an old drug revisited.

Zor M, Aydur E, Dmochowski R Int Urogynecol J. 2014; 26(7):959-66.

PMID: 25480503 DOI: 10.1007/s00192-014-2585-5.

Effects of flavoxate hydrochloride on voltage-dependent Ba2+ currents in human detrusor myocytes at different experimental temperatures.

Tomoda T, Zhu H, Iwasa K, Aishima M, Shibata A, Seki N Naunyn Schmiedebergs Arch Pharmacol. 2007; 376(3):195-203.

PMID: 17909749 DOI: 10.1007/s00210-007-0190-6.

Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro.

Truss M, Uckert S, Stief C, Forssmann W, Jonas U Urol Res. 1996; 24(3):129-34.

PMID: 8839479 DOI: 10.1007/BF00304075.

Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.

ODwyer P, SHOEMAKER D, ZAHARKO D, Grieshaber C, Plowman J, Corbett T Cancer Chemother Pharmacol. 1987; 19(1):6-10.

PMID: 3545524 DOI: 10.1007/BF00296246.